Literature DB >> 23960778

The association between nonsteroidal anti-inflammatory drugs and potassium concentrations: A pharmacoepidemiological study in Saudi Arabia.

Hisham Aljadhey1.   

Abstract

OBJECTIVE: Several nonsteroidal anti-inflammatory drugs (NSAIDs) have been linked to cardiac death. The mechanism that is responsible for this adverse effect appears to be ischemic insult; however, another possible mechanism involves hyperkalemia. The objective of the present study was to determine the feasibility of conducting pharmacoepidemiological studies in Saudi Arabia using refill prescription data to investigate the association between NSAIDs and increased serum potassium concentrations.
METHODS: This retrospective cohort study included patients from an academic medical center in Riyadh, Saudi Arabia. The patients who were recently prescribed NSAIDs were compared to a control group of paracetamol users, with respect to the drugs' effects on serum potassium concentrations. The covariates that affected the potassium concentration or the use of NSAIDs were controlled for in the analysis. The studied outcome was the first serum potassium concentration of more than 5 mEq/L.
RESULTS: A total of 184 patients were prescribed NSAIDs (n = 101) or paracetamol (n = 83) and met the inclusion criteria. Compared to the control group, the patients who received NSAIDs were more likely to be women, were less likely to use angiotensin-converting enzyme inhibitors, and were more likely to have lower baseline serum creatinine concentrations. The other baseline characteristics were similar between the patients in the NSAID group and the patients who received paracetamol. Compared to the patients who were prescribed paracetamol, those who were prescribed NSAIDs did not have an increased risk of hyperkalemia (odds ratio, 1.1, 95% confidence interval, 0.17-6.7, P = 0.95).
CONCLUSION: In the present, small feasibility study, no increase in the risk of hyperkalemia was associated with NSAIDs compared to paracetamol. The present study was exploratory and included only a small number of patients; therefore, this study may not be sufficiently powered to detect small differences between the groups. Future studies with larger sample sizes are needed to investigate the association between NSAIDs and hyperkalemia.

Entities:  

Keywords:  NSAIDs; Pharmacoepidemiology; Potassium

Year:  2011        PMID: 23960778      PMCID: PMC3745074          DOI: 10.1016/j.jsps.2011.08.002

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


  23 in total

1.  Hyperkalaemia with cyclooxygenase-2 inhibition and hypoaldosteronism.

Authors:  Q Lam; H-G Schneider
Journal:  Intern Med J       Date:  2005-09       Impact factor: 2.048

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

3.  Use of the UK General Practice Research Database for pharmacoepidemiology.

Authors:  L A García Rodríguez; S Pérez Gutthann
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

4.  Developing the Sentinel System--a national resource for evidence development.

Authors:  Rachel E Behrman; Joshua S Benner; Jeffrey S Brown; Mark McClellan; Janet Woodcock; Richard Platt
Journal:  N Engl J Med       Date:  2011-01-12       Impact factor: 91.245

5.  Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

Authors:  S K Swan; D W Rudy; K C Lasseter; C F Ryan; K L Buechel; L J Lambrecht; M B Pinto; S C Dilzer; O Obrda; K J Sundblad; C P Gumbs; D L Ebel; H Quan; P J Larson; J I Schwartz; T A Musliner; B J Gertz; D C Brater; S L Yao
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

6.  Incidence of hyperkalaemia induced by indomethacin in a hospital population.

Authors:  A Zimran; M Kramer; M Plaskin; C Hershko
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

7.  Ketorolac-induced acute renal failure and hyperkalemia.

Authors:  M Kelley; B Bastani
Journal:  Clin Nephrol       Date:  1995-10       Impact factor: 0.975

Review 8.  The management of hyperkalemia in patients with cardiovascular disease.

Authors:  Apurv Khanna; William B White
Journal:  Am J Med       Date:  2009-03       Impact factor: 4.965

9.  Ketorolac-induced acute renal failure and hyperkalemia: report of three cases.

Authors:  L Haragsim; R Dalal; H Bagga; B Bastani
Journal:  Am J Kidney Dis       Date:  1994-10       Impact factor: 8.860

10.  Evaluating medication effects outside of clinical trials: new-user designs.

Authors:  Wayne A Ray
Journal:  Am J Epidemiol       Date:  2003-11-01       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.